Bronchogen
Also known as: Bronchogen · Ala-Glu-Asp-Leu (AEDL) · Ala-Asp-Glu-Leu (ADEL — as printed in one primary paper) · Bronchial Cytogen peptide
Research focus
Lung & bronchi — proposed support of bronchial and respiratory epithelial tissue
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
No Human Data
Origin
Bronchogen is a synthetic short peptide (a ‘Cytogen’) attributed to the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a defined-sequence successor to earlier animal-tissue respiratory peptide preparations and marketed for bronchial/respiratory support. It is most often reported as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), although the primary literature is inconsistent — at least one peer-reviewed paper prints the sequence as Ala-Asp-Glu-Leu (Monaselidze et al., 2011). It is not FDA-approved and is not a registered drug in the US or EU.
Plain-language summary
Bronchogen is a lab-made short peptide from the Russian 'Khavinson' Cytogen family, marketed for lung and breathing support. It does have a small real research record — but it is laboratory work on cells and DNA, not clinical studies in people with lung disease: experiments showing it nudges differentiation markers in cultured human bronchial cells, and that it binds DNA in test tubes. There are no human clinical trials, no studies showing it improves any respiratory condition, and even the published amino-acid sequence is inconsistent (most papers print Ala-Glu-Asp-Leu, one prints Ala-Asp-Glu-Leu). It is not FDA-approved and is sold online only as an unregulated 'research chemical.'
Claimed mechanism (as reported)
Bronchogen is proposed, within the Khavinson 'peptide bioregulator' model, to act as an epigenetic regulator that penetrates cells and binds DNA in a sequence-preferential way to influence tissue-specific gene expression. The most direct published data are in-vitro: in cultures of human bronchial epithelial cells, bronchogen reportedly stimulated the differentiation markers CXCL12 and Hoxa3, with a larger effect in aged (late-passage) cultures (Khavinson et al., Bull Exp Biol Med, 2012). Biophysical studies report that it binds DNA (preferentially CTG-containing sequences) and modestly raises DNA melting temperature (Fedoreyeva et al., 2011; Monaselidze et al., 2011). No receptor-level mechanism and no in-vivo respiratory mechanism have been established; the model rests on in-vitro and biophysical work from a small set of affiliated groups.
Evidence summary
A small, genuinely on-topic preclinical literature exists — unusually for a Cytogen, some of it uses actual bronchial cells. In aging human bronchial epithelial cultures, bronchogen reportedly stimulated the differentiation factors CXCL12 and Hoxa3 (Khavinson et al., 2012). Biophysical/biochemical studies report sequence-preferential DNA binding and a small increase in DNA thermal stability (Fedoreyeva et al., 2011; Monaselidze et al., 2011). However, there are no in-vivo respiratory-disease models, no pharmacokinetics, and no human clinical or observational studies in the peer-reviewed literature as of 2026, and the work originates from a small affiliated network. The amino-acid sequence is reported inconsistently across primary papers (Ala-Glu-Asp-Leu in most; Ala-Asp-Glu-Leu in one).
What the research reports
Peptides tissue-specifically stimulate cell differentiation during their aging (bronchogen in bronchial cells)
Grade DKhavinson VKh, Linkova NS, Polyakova VO et al. · Bulletin of Experimental Biology and Medicine · 2012
Reported finding: Bronchogen (Ala-Glu-Asp-Leu) reportedly stimulated tissue-specific expression of the differentiation markers CXCL12 and Hoxa3 in bronchial epithelial cells, with a more pronounced effect in aged (late-passage) cultures.
Sample: Cultured human bronchial epithelial cells (with pancreatic cells / prostatic fibroblasts for related peptides)
Methodology: D — in-vitro human cell culture, single group
Limitations: In-vitro only; differentiation-marker readouts, not respiratory outcomes; single originating group.
Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability
Grade DMonaselidze JR, Khavinson VKh, Gorgoshidze MZ et al. · Bulletin of Experimental Biology and Medicine · 2011
Reported finding: Bronchogen acted as a DNA-stabilizing agent, raising DNA melting temperature by ~3.1°C within a narrow concentration range; binding was described as strong but not base-pair-specific. Notably, this paper prints the sequence as Ala-Asp-Glu-Leu.
Sample: Calf thymus and mouse liver DNA in vitro
Methodology: D — biophysical (calorimetry) study, no biological outcome
Limitations: Pure biophysics with no cellular or in-vivo relevance; sequence printed here differs from other papers.
Penetration of short peptides into the nucleus and sequence-preferential DNA binding (incl. bronchogen)
Grade DFedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF · Biochemistry (Moscow) · 2011
Reported finding: Labeled short peptides including bronchogen (Ala-Glu-Asp-Leu) penetrated the nucleus of HeLa cells and bound DNA preferentially at CTG-containing sequences, supporting the proposed epigenetic-binding model.
Sample: HeLa cells; fluorescently labeled oligonucleotides
Methodology: D — in-vitro HeLa cell + biochemistry, single group
Limitations: In-vitro cancer-cell line and oligonucleotide assays; mechanistic, not therapeutic; single group.
Administration reported in studies
Published studies use bronchogen in vitro (added to cell cultures or DNA preparations); there is no established human dosing and no pharmacokinetic data. Vendor 'Cytogen' products imply oral capsule courses, but no human study supports any regimen. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
No human safety data exist. There are no clinical trials, pharmacokinetic studies, or systematic adverse-event reports. The originating group describes its short peptides as low-toxicity in preclinical work, but absence of reported harm in a few single-group in-vitro studies is not evidence of human safety. Material sold online is unregulated and untested for identity, purity, or sterility by any independent authority.
US legal status
Not FDA-approved. Not on the 503A compoundable bulk substances list. Not legally compoundable for human clinical use in the United States. Sold online only as a 'research chemical' or unregulated supplement — vendors in that channel are unregulated and not verified by TPC.
Open research questions
- ? Does bronchogen show any benefit in an actual in-vivo respiratory-disease model, not just cell cultures?
- ? Which sequence — Ala-Glu-Asp-Leu or Ala-Asp-Glu-Leu — is the compound actually studied and sold?
- ? Is there any human pharmacokinetic or safety data?
- ? Do the bronchial-cell differentiation effects replicate outside the originating institute?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →